摘要
目的 分析妊娠期高血压患者应用拉贝洛尔加硫酸镁治疗对母婴预后的影响，方法 选取本院产科2019年4月至2022年4月已确诊患妊娠期高血压的患者62例随机分成对照组和实验组作为研究对象，对实验组中的31名患者采用拉贝洛尔加硫酸镁治疗，对照组仅采用硫酸镁治疗，为排除其他条件的干预，两组实验患者均实施常规性基础护理，实验过程中进行数据记录与分析。结果 发现采用拉贝洛尔加硫酸镁治疗与仅采用硫酸镁治疗的患者总有效率分别为96.8%（30/31）、80.6%（25/31），P<0.05（差异具有统计学意义）。实验组妊娠结局明显优于对照组，由于妊娠结局与母婴预后呈正相关，因此得出母婴预后效果实验组明显优于对照组（P<0.05）。结论 妊娠期高血压患者应用拉贝洛尔加硫酸镁治疗，能有显著提高治疗效果，对母婴预后有显著改善，值得临床推广。
关键词： 妊娠期高血压；硫酸镁；拉贝洛尔；妊娠结局；母婴预后
Abstract
Objective To analyze the effect of labetalol plus magnesium sulfate treatment on maternal and infant prognosis in patients with gestational hypertension. Methods 62 patients diagnosed with gestational hypertension in the obstetrics department of our hospital from April 2019 to April 2022 were selected. The patients were randomly divided into the control group and the experimental group as the research objects. 31 patients in the experimental group were treated with labetalol plus magnesium sulfate, and the control group was only treated with magnesium sulfate. In order to exclude other interventions, the experimental patients in both groups were treated with Routine basic care was implemented, and data recording and analysis were performed during the experiment. Results showed that the total effective rates of patients treated with labetalol plus magnesium sulfate and those treated with magnesium sulfate alone were 96.8% (30/31) and 80.6% (25/31), respectively, P<0.05 (the difference was statistically significant) . The pregnancy outcome of the experimental group was significantly better than that of the control group. Because the pregnancy outcome was positively correlated with the prognosis of mother and baby, it was concluded that the prognosis of the mother and baby in the experimental group was significantly better than that in the control group (P<0.05). Conclusion The application of labetalol plus magnesium sulfate in the treatment of gestational hypertension can significantly improve the therapeutic effect and improve the prognosis of mother and child, which is worthy of clinical promotion.
Key words： Gestational hypertension; Magnesium sulfate; Labetalol; Pregnancy outcome; Maternal and infant prognosis
参考文献 References
[1] 何娟.硫酸镁、硝苯地平、拉贝洛尔治疗妊娠高血压综合征（妊高症）的效果以及安全性[J].当代临床医刊,2020,(1).25-26.
[2] 黄金莲.拉贝洛尔联合硫酸镁治疗妊高症的临床效果研究[J].东方药膳,2020,(1):16.
[3] Monika Sharma,Sita Thakur,Kamal Singh,Shashank Shekhar. Comparative maternal outcomes of oral nifedipine and intravenous labetalol for severe hypertension during pregnancy: an open label randomized controlled trial[J]. International Journal of Reproduction Contraception Obstetrics and Gynecology,2020,9(7).
[4] 马宏丽.观察拉贝洛尔联合硫酸镁治疗妊高症的疗效[J].中国保健营养,2020,30(22):66.
[5] 赵书利,钱秋然.拉贝洛尔联合硫酸镁对妊娠高血压的疗效分析[J].深圳中西医结合杂志,2020,30(13):117-118.
[6] 徐影,安洪宾.重度妊娠高血压疾病应用拉贝洛尔联合硫酸镁治疗的效果分析[J].中国实用医药,2019,14(5):122-124.
[7] 续靖宁,徐琳,刘进军. 拉贝洛尔联合硫酸镁对妊娠期高血压的治疗效果及对分娩结局的影响[J]. 实用临床医药杂志,2020,24(20):87-89,93.
[8] Wu Y,Wang D-J,Zhang Y,Zhang Y-X,Zhang R. Regulation of magnesium sulfate combined with nifedipine and labetalol on disease-related molecules in serum and placenta in the treatment of preeclampsia.[J]. European review for medical and pharmacological sciences,2020,24(9):3.